Arctic Bioscience will present its latest drug development project, ABS403, at the Glaucoma 360 New Horizons Forum in San Francisco on January 30, 2026. The presentation, led by Medical Director Runhild Gammelsæter, will focus on innovative approaches to drug dosing and delivery aimed at reducing inflammation and promoting neuroprotection in glaucoma, a disease that currently has no cure and can lead to blindness. The ABS403 project is based on promising results from an initial pilot study in patients with primary open-angle glaucoma (POAG).
The company is seeking partners and investors to support further clinical development of ABS403. Arctic Bioscience specializes in pharmaceutical and nutraceutical products derived from marine bioactive compounds and is also developing HRO350, an oral drug candidate for mild-to-moderate psoriasis.
**Why this matters**
Glaucoma is a leading cause of irreversible blindness worldwide, and current treatments do not offer a cure. Developing new therapies that address inflammation and protect nerve cells could significantly improve patient outcomes. Arctic Bioscience’s work represents a potential advancement in glaucoma treatment and highlights the importance of innovative drug delivery systems in managing chronic eye diseases.